TP53 and breast cancer: In the present study, immunohistochemical staining was used to determine the prognostic significance of ER, PR, p53, c-erbB2, bcl-2, and Ki-67 expression in a homogenous patient cohort who received AC/T as adjuvant therapy for stage III breast cancer at a single institution.